NYSE:AGE AgeX Therapeutics (AGE) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.22▼$16.5152-Week Range N/AVolume3,700 shsAverage Volume3,849 shsMarket Capitalization$11.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsHeadlinesOwnershipTrendsStock AnalysisEarningsHeadlinesOwnershipTrends Get AgeX Therapeutics alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About AgeX Therapeutics Stock (NYSE:AGE)AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.Read More Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE AGE Stock News HeadlinesSeptember 10, 2024 | benzinga.comRussell Skibsted's Net WorthAugust 18, 2024 | finance.yahoo.comSerina Therapeutics, Inc. (SER)September 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.August 16, 2024 | finance.yahoo.comBillionaires are betting on anti-ageing research, but can ageing really be cured?July 23, 2024 | finance.yahoo.comGLP Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsightMay 18, 2024 | seekingalpha.comSER Serina Therapeutics, Inc.May 7, 2024 | finance.yahoo.comStem Cell Collaboration, R&D, and Licensing Deals Analysis Report 2024 with Directory of 162 Agreements Signed Since 2016March 26, 2024 | globenewswire.comSerina Therapeutics Announces Completion of Merger with AgeX TherapeuticsSeptember 16, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 23, 2024 | finanznachrichten.deAgeX Therapeutics, Inc.: AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsMarch 22, 2024 | globenewswire.comAgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial ResultsFebruary 27, 2024 | businesswire.comAGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGEFebruary 7, 2024 | msn.comAgeX Therapeutics Secures $500K Convertible Note DealFebruary 7, 2024 | msn.comAgeX Therapeutics Expands Ties with JuvVentures Equity DealJanuary 25, 2024 | msn.comWhy IBM Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving PremarketDecember 13, 2023 | morningstar.comAgeX Therapeutics Inc AGENovember 17, 2023 | msn.comWhat's Going On With Penny Stock AgeX Therapeutics?November 17, 2023 | finance.yahoo.comSerina Therapeutics Announces POZ Polymer Technology License Agreement with PfizerSee More Headlines Receive AGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AgeX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today9/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:AGE CUSIPN/A CIK1708599 Webwww.agexinc.com Phone(510) 671-8370Fax510-871-4154Employees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($13.0282) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,800,000.00 Net Margins-10,424.65% Pretax Margin-10,430.28% Return on EquityN/A Return on Assets-120.90% Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.36 Sales & Book Value Annual Sales$140,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($16.07) per share Price / BookN/AMiscellaneous Outstanding Shares1,080,000Free Float1,008,000Market Cap$11.99 million OptionableNot Optionable Beta1.18 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Joanne M. Hackett Ph.D. (Age 46)Interim CEO & Chairman of the Board Comp: $55.74kMs. Eun-Jae Park CPA (Age 52)Chief Financial Officer Comp: $295.29kDr. Ivan LabatChief Information OfficerMs. Judith Segall (Age 71)Secretary Key CompetitorsMid-Southern BancorpNASDAQ:MSVBVaccitechNASDAQ:VACCReneo PharmaceuticalsNASDAQ:RPHMDURECTNASDAQ:DRRXRallybioNASDAQ:RLYBView All Competitors AGE Stock Analysis - Frequently Asked Questions When did AgeX Therapeutics' stock split? Shares of AgeX Therapeutics split on Monday, March 18th 2024. The 8-5 split was announced on Monday, March 18th 2024. The newly created shares were distributed to shareholders after the market closes on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split. What other stocks do shareholders of AgeX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AgeX Therapeutics investors own include Biocept (BIOC), Allena Pharmaceuticals (ALNA), Co-Diagnostics (CODX), Moleculin Biotech (MBRX), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS) and AIM ImmunoTech (AIM). This page (NYSE:AGE) was last updated on 9/16/2024 by MarketBeat.com Staff From Our PartnersMore Than 30 Federal Agencies Buy From This Cybersecurity TechIn January of 2022 Ukraine was hit by an especially nasty piece of malware, named WhisperGate. By then Ukra...Capital Trends | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredBREAKING NEWS: AI Tech Now Used to Stop School ShootersTwo seconds. That's all it takes for Knightscope's Automated Gunshot Detection to notify authorities and map a...Market JAR | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia needs these 3 companies on a new $1 trillion SuperprojectNvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And i...Weiss Ratings | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AgeX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AgeX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.